Locations:
Search IconSearch
April 4, 2018/Cancer/News & Insight

Social Media and Journal Clubs: The Ultimate Peer Review?

An oncologist weighs in

social-media_650x450

ByAaron Gerds, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The Cotton Club, The Breakfast Club and journal club. Like other legendary clubs, journal club has centered around an in-person gathering to facilitate the exchange of commentary and ideas on a given topic. The critical evaluation of recent articles conducted in journal clubs serves as a building block for medical education, evidence-based guidelines and quality improvement initiatives. From residency training, I have very vivid — dare I say fond? — memories of journal club at Hines VA Hospital getting into the nitty gritty of numbers needed to treat with then Chairman Brian Schmitt, MD, MPH. For the past 180 years, from Sir James Paget to Gordon Guyatt, MD, MSc, journal clubs have been steadfast with a very gradual evolution, but the technology revolution is shaking things up.

Social media, including Twitter, has changed the way we communicate. In addition to focused composition and the introduction of emoji, it has also eliminated distance and time. Discussions including thousands can be had instantly across the globe. It has been argued that social media has dumbed down discourse, reducing it to a series of likes or retweets. Despite its limitations, it can be a powerful tool in the appraisal of the medical literature.

With most manuscripts posted on publishers’ websites well in advance of print, the peer review process can occur almost instantaneously. Social media also enables the readership to interact directly with the authors.

With such a large volume of users, critiques presented and validated are essentially crowdsourced, and conversely, individuals can provide insight on how local context may affect the application of results in their own practice. Social media invites its users to come off the bench and get into the game, identifying quality and refuting misinterpretation by a simple post for many, with others taking the next step into content creation. One key element yet to be clarified as things move forward is how these contributions will be measured and how faculty will get academic credit for participating in online forums.

Advertisement

While time will tell if Twitter and social media are the ultimate peer review, it is clear that they can be a powerful tool in conducting academic medicine. I wonder if William Osler would share his critiques in 280 characters or less.

Dr. Gerds is a staff physician in the Department of Hematology and Medical Oncology and publishes in medical literature about social media use. Follow him on Twitter @AaronGerds.

Advertisement

Related Articles

Medical illustration of blood cells
August 25, 2026/Cancer/Benign Hematology

Understanding Rebalancing Agents

Newer class of medications evolves care models for patients with hemophilia

Patient greeting physician
August 12, 2026/Cancer/Benign Hematology

Classical Hematology 2.0

Improving access to specialists

Large meningiolma
August 6, 2026/Cancer/Brain Tumor

Case Study: Patient with Large Meningioma Thriving After Treatment

Dotatate PET/CT scan and molecular testing informed treatment trajectory

Young couple cooking
July 27, 2026/Cancer/Patient Support

Empowering Cancer Survivors through Lifestyle Medicine

A proactive, framework-based approach

Physician checking patient's heart rate
July 15, 2026/Cancer

First-Generation BTK Inhibitors Associated with Higher Risk of Cardiac Events

Patients on ibrutinib were more than twice as likely to experience atrial fibrillation or heart failure than those on second-generation alternatives.

Thyroid cancer illustration
July 13, 2026/Cancer/News & Insight

New ASCO Guidelines Help Clinicians Navigate Rapid Shifts in Thyroid Cancer Treatment

Expert recommendations introduce use of targeted agents

AML cells in blood flow
July 10, 2026/Cancer/Blood Cancers

Ziftomenib + Chemotherapy Drives Deep Remission in Frontline NPM1-m/KMT2A-r AML

Combination therapy may soon represent new standard of care

Researcher with microscope
June 26, 2026/Cancer

Testosterone May Offer Anti-Tumor Activity in Glioblastoma

Research findings offer clues for improving disease outcomes in men

Ad